Recombinant Human IL36A/IL-1F6, N-His from ProteoGenix; catalogue ARO-P13032; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Recombinant Human IL36A/IL-1F6 is a cytokine protein that belongs to the IL-1 family. It is also known as interleukin-36 alpha (IL-36α) or interleukin-1 family member 6 (IL-1F6). This protein is produced by recombinant DNA technology and is used in various research and therapeutic applications. In this article, we will discuss the structure, activity, and applications of Recombinant Human IL36A/IL-1F6.
Recombinant Human IL36A/IL-1F6 is a small protein consisting of 159 amino acids. It has a molecular weight of approximately 18 kDa. The protein contains a signal peptide of 22 amino acids, which is cleaved during post-translational processing. The mature protein has a predicted isoelectric point of 8.8 and a predicted N-terminal pyroglutamate residue. The crystal structure of Recombinant Human IL36A/IL-1F6 has been determined and it shows a typical beta-trefoil fold, which is characteristic of the IL-1 family of cytokines.
Recombinant Human IL36A/IL-1F6 is a proinflammatory cytokine that plays a key role in the innate immune response. It exerts its biological activity by binding to the IL-36 receptor (IL-36R) and activating downstream signaling pathways. IL-36R is a heterodimeric receptor complex consisting of IL-36R and IL-1 receptor accessory protein (IL-1RAcP). Upon binding, Recombinant Human IL36A/IL-1F6 induces the production of proinflammatory cytokines such as IL-6, IL-8, and TNF-α, as well as chemokines such as CXCL1 and CXCL8. It also promotes the recruitment of immune cells to the site of infection or injury.
Recombinant Human IL36A/IL-1F6 has been shown to have a role in various inflammatory conditions such as psoriasis, rheumatoid arthritis, and inflammatory bowel disease. It has also been implicated in the pathogenesis of certain autoimmune diseases. Studies have shown that elevated levels of IL-36α are present in the skin lesions of psoriasis patients, and blocking its activity can improve the symptoms of the disease.
Recombinant Human IL36A/IL-1F6 has a wide range of applications in both research and therapeutic settings. Some of the key applications include:
Recombinant Human IL36A/IL-1F6 is commonly used in research to study the role of IL-36 signaling in various diseases and conditions. It is also used to investigate the molecular mechanisms underlying the proinflammatory effects of IL-36α. The protein can be used in in vitro experiments to stimulate immune cells and measure the production of cytokines and chemokines. It can also be used in in vivo studies to evaluate its effects on disease progression and immune response.
Recombinant Human IL36A/IL-1F6 has potential therapeutic applications in the treatment of inflammatory and autoimmune diseases. It can be used as a drug target to develop novel therapies for conditions such as psoriasis, rheumatoid arthritis, and inflammatory bowel disease. In addition, the protein can also be used as a biomarker for disease diagnosis and monitoring treatment response.
Recombinant Human IL36A
ProteoGenix catalogue number ARO-P13032. For research use only.
Host: Escherichia coli (E.coli); Expression system: Prokaryotic expression; Molecular weight: 19.85 kDa; Fragment: Met1-Phe158; Buffer: Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol..
Available configurations: 50ug, 100ug, 1mg.
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
